InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,071.63
(
0.00%
)
US TECH 100
16,880.00
(
-1.06%
)
Dow Jones
38,460.92
(
0.00%
)
Brent Oil
87.49
(
0.30%
)
Bitcoin
64,128.20
(
-0.24%
)
Post# of 29247
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119469
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biotech_researcher post# 17509

Tuesday, 11/06/2018 10:44:22 AM

Tuesday, November 06, 2018 10:44:22 AM

Post# of 29247

I’ve followed NVO for a while looking for an entry point. The CEO of Lilly was just interviewed on CNBC and was excited about a compound that appears to be a direct competitor to Saxenda in the final stage of its phase 3 trial.

If the drug LLY’s CEO was talking about is LY3298176, it hasn’t yet started phase-3. (LY3298176 is a dual GIP and GLP-1 agonist.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up